Renovacor, Inc.

Renovacor, Inc. is a cardiovascular gene therapy company that completed a business combination with Chardan NexTech Acquisition 2 Corp., trading on Nasdaq under the ticker CHAQ. The blank-check vehicle was sponsored by Chardan Healthcare Investments 2 LLC and completed its initial public offering in 2021, targeting the healthcare and life sciences sector. An 8-K filing submitted to the Securities and Exchange Commission on September 20, 2022, under accession number 0001193125-22-247756, reflects a material event tied to that transaction. Renovacor's pipeline focuses on gene therapies for genetic forms of heart failure, including dilated cardiomyopathy. Sign up at SpacDesk for full filing history, sponsor data, and deal analytics on CHAQ and thousands of other SPAC transactions.